XML 17 R6.htm IDEA: XBRL DOCUMENT v3.25.0.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 6 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Cash Flows from Operating Activities    
Net loss $ (4,951,596) $ (4,408,807)
Adjustments to reconcile net loss to cash used in operating activities:    
Depreciation and amortization 488,669 479,044
Amortization of right-of-use assets 122,077 118,829
Non-cash loss on foreign currency translation, net 555
Provision for inventory obsolescence 69,016
Share-based compensation 214,045
Non-cash refund of R&D expenditure claims (109,736) (78,281)
Fair value gain on revaluation of holdback Series C preferred Stock (175,738)
Non-cash other operating activities 41,806 15,529
Changes in operating assets and liabilities:    
Accounts receivable 163,624 31,027
Inventories 76,257 (31,159)
Grant receivable / deferred grant income 93,843
Research and development tax incentive receivable 149,645 209,591
Deferred charges (127,586)
Other current assets 148,888 221,190
Accounts and other payables (792,051) (630,570)
Other long-term liabilities (135,678) 5,091
Operating lease liabilities (332) (100,151)
Net cash used in operating activities (4,711,968) (4,180,991)
Cash flows from Investing Activities    
Amount invested on construction in progress (8,936) (56,669)
Net cash used in investing activities (8,936) (56,669)
Cash flows from Financing Activities    
Proceeds from issuance of common stock and warrants 686,881 1,342,296
Proceeds from exercise of warrants 7,939
Proceeds from issuance of preferred stock 3,036,223
Payment of equity issuance costs (20,626) (592,355)
Net cash provided by financing activities 674,194 3,786,164
Effect of foreign exchange rates on cash and cash equivalents (15,179) 33,256
Net decrease in cash and cash equivalents (4,061,889) (418,240)
Cash and cash equivalents, beginning of period 6,304,098 1,537,244
Cash and cash equivalents, end of the period 2,242,209 1,119,004
Non-cash investing and financing activities    
Conversion of preferred shares into common shares 57,287
Conversion of holdback Series C Preferred Stock into common stock 32,762
Issuance of common stock upon cashless exercise of Series F warrants 6,122
Amount receivable for issuance of common shares $ 10,363